Passage Bio Inc reports results for the quarter ended September 30 - Earnings Summary

Passage Bio

13/11/2024 14:16

* Passage Bio Inc  PASG.OQ  reported a quarterly adjusted
loss
of 31 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -49 cents.  The mean expectation of
five analysts for the quarter was for a loss of 23 cents per
share. Wall Street expected results to range from -31 cents
to -13 cents per share.
    * Reported revenue was zero​; analysts expected $3.33
million. 
    * Passage Bio Inc's reported EPS for the quarter was a loss
of 31
cents​.
    * The company reported a quarterly loss of $19.34 million.
    * Passage Bio Inc shares had fallen by 4.6% this quarter and
lost 33.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Passage Bio Inc
is 5.50 
This summary was machine generated from LSEG data November 13 at
02:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.23          -0.31          Missed
 Jun. 30 2024      -0.31          -0.26          Beat
 Mar. 31 2024      -0.36          -0.30          Beat
 Dec. 31 2023      -0.40          -0.30          Beat